cell culture systems, and was used in this study to monitor glutamine in plasma samples (plasma separator tubes; Becton Dickinson B.V., Breda, the Netherlands). For pre-validation of the analyser, we used water-based controls from the supplier of this analyser, and the measurements appeared reproducible. Control measurements were as follows: level 1 mean (± standard deviation) was 1.06 ± 0.061 mmol/l, the CV (coefficient of variation) was 5.7%, and n = 143; level 2 mean was 5.31 ± 0.400 mmol/l, the CV was 7.5%, and n = 152. Using home-made serum/plasma controls, we obtained the following results: heparin pool 1, 0.558 ± 0.056 mmol/l, CV = 10.1%, n = 45; serum pool, 1.038 ± 0.086 mmol/l, CV = 8.3%, n = 45; and heparin pool 2, 5.279 ± 0.259 mmol/l, CV = 4.9%, n = 42. We established that plasma glutamine levels were stable when plasma was separated from cells within 3 h after sampling and frozen until analysis (or measured within 3 h after plasma preparation) (Fig. 1) . No significant differences in plasma glutamine levels were observed in outpatients (mean difference In outpatients (n = 51), we obtained a plasma glutamine reference interval, which ranged from 0.22-0.59 mmol/l (Fig. 2) . 
